Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Is Merck's Dig at Pfizer's COVID-19 Pill Justified?


Merck (NYSE: MRK) and Pfizer (NYSE: PFE) could soon compete against each other in the oral COVID-19 therapy market. But Merck has already started a war of words with Pfizer even before either drug has won authorization. In this Motley Fool Live video recorded on Dec. 8, Motley Fool contributors Keith Speights and Brian Orelli discuss whether or not Merck's recent dig at Pfizer's COVID-19 pill is justified.

Continue reading


Source Fool.com

Like: 0
MRK
Share

Comments